Angiogenesis

Angiostatin, radiation therapy safe as a combination cancer treatment

Published in Cancer Weekly, July 2nd, 2002

EntreMed, Inc. (ENMD), released phase I clinical data that Angiostatin, when combined with radiation therapy, is safe with no dose-limiting toxicity in patients with cancers that require radiation therapy.

The data were reported at the American Society of Clinical Oncology annual meeting. Tumor responses were demonstrated in 90% of patients who entered the trial with measurable disease in the radiation field. Also, no clinically significant side effects over what was anticipated from the radiation therapy were reported.

Dr. Ed Gubish, EntreMed president and chief operating officer said, "With these phase I results, we will move Angiostatin forward...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry